Comparative Pharmacology
Head-to-head clinical analysis: CEPTAZ versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPTAZ versus SEFFIN.
CEPTAZ vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic